Characterization of sleep apnea among a sample of adults from Samoa

Lacey W. Heinsberg; Alysa Pomer; Brian E. Cade; Jenna C. Carlson; Take Naseri; Muagututia Sefuiva Reupena; Satupa’itea Viali; Daniel E. Weeks; Stephen T. McGarvey; Susan Redline; Nicola L. Hawley

doi:10.1101/2023.11.16.23298644

ABSTRACT

Sleep apnea is a public health concern around the world, but little research has been dedicated to examining this issue in low- and middle-income countries, including Samoa. Using data collected through the Soifua Manuia (“Good Health”) study, which aimed to investigate the impact of the body mass index (BMI)-associated genetic variant rs373863828 in CREB3 Regulatory Factor (CREBRF) on metabolic traits in Samoan adults, we examined the sample prevalence and characteristics of sleep apnea using data collected with a validated home sleep apnea device (WatchPAT, Itamar). A total of 330 participants (sampled to overrepresent the obesity-risk allele of interest) had sleep data available. Participants (53.3% female) had a mean (SD) age of 52.0 (9.9) years and BMI of 35.5 (7.5) kg/m² and 36.3% of the sample had type 2 diabetes. Based on the 3% and 4% apnea hypopnea indices (AHI) and the 4% oxygen desaturation index (ODI), descriptive analyses revealed that many participants had potentially actionable sleep apnea defined as >5 events/hr (87.9%, 68.5%, and 71.2%, respectively) or clinically actionable sleep apnea defined as ≥15 events/hr (54.9%, 31.5%, and 34.5%, respectively). Sleep apnea was more severe in men; for example, clinically actionable sleep apnea (≥15) based on the AHI 3% definition was observed in 61.7% of men and 48.9% of women. Correction for non-representational sampling related to the CREBRF obesity-risk allele resulted in only slightly lower estimates. Across the AHI 3%, AHI 4%, and ODI 4%, multiple linear regression revealed associations between a greater number of events/hr and higher age, male sex, higher body mass index, higher abdominal-hip circumference ratio, and geographic region of residence. Our study identified a much higher frequency of sleep apnea in Samoa compared with published data from other studies, but similar predictors. Continued research addressing generalizability of these findings, as well as a specific focus on diagnosis and affordable and equitable access to treatment, is needed to alleviate the burden of sleep apnea in Samoa and around the world.

Competing Interest Statement

LWH, JCC, BEC, DEW, STM, SR, and NLH report funding from the National Institutes of Health during the conduct of this study. SR reports grants and personal fees from Jazz Pharma, personal fees from Eisai Inc, and personal fees from Eli Lilly outside of the submitted work. The funders had no role in the design of the study; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results.

Funding Statement

Research reported in this publication was supported by the National Institutes of Health under award numbers R01HL093093, R01HL133040, and K99HD107030. The sleep studies and SR were partially funded by R35135818. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Boards (IRB) at Yale and Brown Universities, with Yale University serving as the IRB of record (1604017547). Data analysis activities at the University of Pittsburgh were reviewed by their IRB and were determined to be exempt (PRO16040077) based on their receipt of only deidentified data. Activities of the Sleep Reading Center were approved by Mass General Brigham (formerly Partners Healthcare). The study was also approved by the Health Research Committee of the Samoa Ministry of Health.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes